2 results
Not approvedWill not start
Objective: To assess whether angiotensin receptor blocker (ARB) use is beneficial in the early phase of the disease, to prevent lung oedema and damage in high risk patients with a proven COVID-19 infection.
Approved WMOCompleted
To evaluate the safety, tolerability, PK, PD and efficacy of intravenous (IV) ATB200 alone and when co-administered with oral AT2221.